CD47 and colorectal cancer: Although it remains uncertain whether this involves activation of the IFN-γ/STAT1 pathway, it suggests that combining CD47 and PD-L1 antibodies after colorectal cancer radiotherapy could enhance therapeutic effects and improve patient survival.